Does Photodynamic Therapy Add Anything to Anti-VEGF Treatments?
November 22, 2009
As reported in AJO, photodynamic therapy (PDT) adds no measurable benefit when used with Lucentis (ranibizumab) versus Lucentis alone.
In a small study of 34 patients, intraocular VEGF and pigment epithelial-derived growth factor were reduced in both groups, but there was not statistical significance between the two. Macular thickness and visual acuity were also similar in the two groups.
What does this mean? While it seems that PDT may have lost more ground in the treatment for AMD, I suppose it is still a viable option for those patients that can not, or will not, undergo and invasive intraocular procedure. Intraocular injections are tough to beat!
Randall V. Wong, M.D.
Jump down to form below to submit your own comments